AAV-MyoAAV 1A vector system (AAV-MyoAAV 1A expression system, AAV-MyoAAV 1A packaging plasmid system) (Amp and Kanamycin) (GeneMedi Owned)

GeneMedi (GM) AAV-MyoAAV 1A Vector system is including: 1) AAV-MyoAAV 1A Rep-Cap plasmid (AAV-MyoAAV 1A-RC plasmid) 2) AAV Helper plasmid 3) AAV expression vectors (overexpression or shRNA).

You can produce AAV-MyoAAV 1A particle in 293T cell line in high titer using GeneMedi's AAV-MyoAAV 1A Rep-Cap plasmid with GM's AAV expression vector (overexpression or shRNA) and AAV helper plasmid.

MyoAAV1A is designed for efficient targeting and transduction of muscle cells. It likely incorporates specific modifications to the AAV1 capsid or uses muscle-specific promoters to enhance its affinity for skeletal and cardiac muscle tissues. This variant may be particularly useful for diseases where localized muscle gene therapy is required.

GeneMedi offers both Ampicillin (Amp) resistance and Kanamycin (Kan) resistance for the AAV Rep-Cap Plasmids, AAV expression Plasmids and AAV helper Plasmid.

Go to AAV vector system >>